Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of�…

Background Tumor mutational burden (TMB) has been correlated with response to CTLA-4
and PD-(L) 1 inhibitors. We explored the association of TMB with outcomes in cohorts A�…

Background Several studies have evaluated the relationship between tumor mutational
burden (TMB) and outcomes of immune checkpoint inhibitors. In the phase II KEYNOTE-158�…

The FDA approved pembrolizumab on June 16, 2020, for the treatment of adult and pediatric
patients with unresectable or metastatic tumor mutational burden–high [TMB-H;≥ 10�…

A recent study in The Lancet Oncology reports that high tumor mutational burden (TMB) is
associated with response to anti-PD-1 pembrolizumab, leading to the second FDA approval�…

PURPOSE The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a
pragmatic basket trial evaluating antitumor activity of approved targeted agents in patients�…

On 16 June 2020, the US Food and Drug Administration (FDA) granted accelerated
approval to pembrolizumab for the treatment of 'adult and pediatric patients with�…

Introduction We evaluated tissue tumor mutational burden (tTMB) and mutations in STK11,
KEAP1, and KRAS as biomarkers for outcomes with pembrolizumab plus platinum-based�…

Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based�…

Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-
1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the�…